Transfers of value to “influencers”: new disclosure obligation for companies in the health sector

Healthcare 2 min
January 21, 2020

The list of beneficiaries of transfers of value subject to compulsory disclosure in the French public “transparency” database include “persons who, in the media or on social media, present one or several health products, in a way to influence the public” –so-called “influencers” – since an Act of 24 July 2019.

A recent decree of 30 December 2019 now specifies the information to be disclosed for the identification of such “influencers”: it is the “denomination under which this person performs its influence activity”. Thus, as opposed to other categories of beneficiaries, it seems that the « denomination » actually used by the influencer will have to be declared, which might be different from the exact identity (name, surname). The term « denomination » is not defined.

It is worth recalling the regulatory background of the “transparency obligations” applicable in France: companies manufacturing or marketing health products, such as medicinal products and medical devices, or providing related services, must disclose on a public website named “Transparence Santé” transfers of value – contracts, payments and any other advantage in cash or in kind (over €10,00) – made, directly or indirectly, to beneficiaries in the health sector, such as healthcare professionals, associations, students, foundations etc.

The French authorities consider that this disclosure obligation applies irrespective of whether the company is located in France or not, and of whether its products are marketed in France or not, as long as the beneficiary exercises its activity in France or is established in France. These territorial criteria may prove difficult to apply when it comes to activities performed on social media by “influencers”.

Additional implementing texts will specify the disclosure obligation with respect to influencers, since the decree of 30 December specifies that its provisions will enter into force on a date provided by an arrêté yet to be published, and at the latest on 1 January 2021.

Written by
Yves Bizollon
Yves Bizollon
I'm a Paris-based partner leading our Intellectual Property Group in France, with over 30 years' experience in IP. I also led the establishment of the Bird & Bird office in Lyon. Thanks to the experience I have acquired over decades working in the sector, I have gained a deep and broad understanding of IP in various areas, on both French and international levels. I have had the chance to handle some of the most significant and complex IP litigations, with a strong focus on patents, in an extensive range of sectors such as pharmaceuticals, food, telecomms, energy, defence and automotive.
Dora Talvard
Dora Talvard
My work is focused on the life sciences and healthcare sectors. I advise clients on a broad range of regulatory aspects. I work hand in hand with the intellectual property, data protection, commercial and corporate lawyers of the firm to provide clients with tailor made advice and solutions.

Related articles

AstraZeneca held liable for additional healthcare costs
In a judgment of 14 October 2020 the District Court The Hague ruled in a landslide decision that AstraZeneca...
A vaccine for COVID 19 –risks and liabilities in international perspective
As the development of vaccines against COVID-19 is progressing, the question becomes urgent who will...
Access to toxicity study reports and protection of commercial interests
Gerard Hogan, Advocate General at the Court of Justice of the European Union (“CJEU”) recently...
Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.